Body size should not be a major factor influencing dose reduction decisions in women with ovarian cancer, according to a cohort study of 806 women with primary invasive epithelial ovarian cancers and receiving adjuvant first-line therapy of carboplatin and paclitaxel, with curative intent. Researchers’ results included:
•Compared with normal-weight women, obese class III women received 38% and 45% lower doses in milligrams/kilogram of body weight of paclitaxel and carboplatin, respectively.
•They also received lower relative dose intensity (RDI) for each agent and for the combined regimen, calculated as average RDI (ARDI).
•Lower ARDI was associated with worse overall survival and ovarian cancer-specific survival.
•At every BMI category, women with ARDI < 85% had worse survival than those without dose reduction.